

5.2 Inclusion criteria

Patients eligible for inclusion in this study have to meet **all** of the following criteria:

1. Patients must have received CAR-T therapy within one of the following:
 - Novartis or Penn sponsored CAR-T treatment trials where CAR-T was given as monotherapy or as combination therapy. (see [Table 14-1](#) for list of clinical trial)
 - Novartis managed access programs (MAP) outside of the commercial setting, i.e. where CAR-T therapy was intended to be given in the setting of a Novartis or Penn sponsored CAR-T treatment trial (see [Table 14-1](#) for the list MAPs)
2. Patients must provide informed consent prior to their entry into this study.

5.3 Exclusion criteria

There are no specific exclusion criteria for this study.

14.1 Appendix 1: Enrollment into LTFU study

Patients who received CAR-T therapy from within one of the protocols listed in [Table 14-1](#) are eligible for enrollment into the LTFU study. [Table 14-1](#) includes active, completed and planned Novartis and/or Penn protocols that administer CAR-T therapy.

Note: this list is subject to change without prior notice and will not warrant a protocol amendment.

Table 14-1 Eligible Novartis and Penn treatment protocols

Clinical Treatment trials	Managed Access Programs
ADPT07A12101	CCTL019B2001X
CCTL019A2101J	CCTL019CFR01I (patient infused prior to July, 2019)
CCTL019A2201	CCTL019ZFR01I (patient infused prior to July, 2019)
CCTL019A2206J	
CCTL019B2101J	
CCTL019B2102J	
CCTL019B2202	
CCTL019B2203J	
CCTL019B2205J	
CCTL019B2208J	
CCTL019B2209J	
CCTL019B2210	
CCTL019C2201	
CCTL019C2202	
CCTL019C2203	
CCTL019CUS02T	
CCTL019E2202	
CCTL019G2201J	
CCTL019H2301	
CCTL019I2301	
CCTL019J2101	
CCTL019J2301	
CCTL019K2201C	
CCTL019K2301	
CCTL019L12101C	
CCTL019Z2203J	
CCTL019ZUS01T	
CYTB323A12101	
UPCC 13BT022	
UPCC 18CT014	
UPCC 19416	